While HFA-ICOS risk predicts cardiac events in patients with breast cancer receiving anthracycline and/or anti-HER2 therapies, future studies should evaluate whether imaging surveillance in higher risk individuals mitigates this risk. This evidence concerns the gene ERBB2 and breast carcinoma.